Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing.

CAMBRIDGE, Mass., January 12, 2025 -- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic...

Jan 12, 2025 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 12, 2025-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

2 days ago · SAGE is currently trading at $24.93, up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at $147.98 up 1.21 percent or $1.78 on the Nasdaq. SHARE THIS POST

Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Sage Therapeutics is a biopharmaceutical company committed to developing novel...

Oct 17, 2024 · Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain ...

Nov 20, 2024 · Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare...

Feb 6, 2023 · Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM).